Regulatory immune cells and functions in autoimmunity and transplantation immunology

Autoimmunity Reviews

Volumn 16, Issue 5, 2017, Pages 435-444

  Papp, Gabor ^a   Boros, Peter ^b   Nakken, Britt ^c   Szodoray, Peter ^c   Zeher, Margit ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Autoimmunity; Regulatory cells; Systemic autoimmune diseases; Tolerance induction; Transplant rejection

Indexed keywords

CYTOKINE; IMMUNOLOGIC FACTOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; MACROPHAGE; MESENCHYMAL STROMA CELL; MIXED CONNECTIVE TISSUE DISEASE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; ORGAN TRANSPLANTATION; REGULATORY B LYMPHOCYTE; REGULATORY T LYMPHOCYTE; REVIEW; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; TRANSPLANTATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY;

AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; TRANSPLANTATION IMMUNOLOGY;

EID: 85019017075     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.03.011     Document Type: Review

References (150)

1. [1] Davies, A.J., Immunological tolerance and the autoimmune response. Autoimmun Rev 7 (2008), 538–543.
2. [2] Nagy, G., Huszthy, P.C., Fossum, E., Konttinen, Y., Nakken, B., Szodoray, P., Selected aspects in the pathogenesis of autoimmune diseases. Mediators Inflamm, 2015, 2015, 351732.
3. [3] Alegre, M.L., Lakkis, F.G., Morelli, A.E., Antigen presentation in transplantation. Trends Immunol 37 (2016), 831–843.
4. [4] Takeuchi, O., Akira, S., Pattern recognition receptors and inflammation. Cell 140 (2010), 805–820.
5. [5] Liu, J., Cao, X., Cellular and molecular regulation of innate inflammatory responses. Cell Mol Immunol 13 (2016), 711–721.
6. [6] Jaehn, P.S., Zaenker, K.S., Schmitz, J., Dzionek, A., Functional dichotomy of plasmacytoid dendritic cells: antigen-specific activation of T cells versus production of type I interferon. Eur J Immunol 38 (2008), 1822–1832.
7. [7] Jongbloed, S.L., Kassianos, A.J., McDonald, K.J., Clark, G.J., Ju, X., Angel, C.E., et al. Human CD141 + (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 207 (2010), 1247–1260.
8. [8] Mueller, S.N., Skin DCs cluster for efficient T cell activation. Nat Immunol 15 (2014), 1004–1005.
9. [9] Woodruff, M.C., Turley, S.J., Chemokine ‘grooming’ by cLECs directs DC migration. Nat Immunol 15 (2014), 595–596.
10. [10] García-González, P., Ubilla-Olguín, G., Catalán, D., Schinnerling, K., Aguillón, J.C., Tolerogenic dendritic cells for reprogramming of lymphocyte responses in autoimmune diseases. Autoimmun Rev 15 (2016), 1071–1080.
11. [11] Sela, U., Olds, P., Park, A., Schlesinger, S.J., Steinman, R.M., Dendritic cells induce antigen-specific regulatory T cells that prevent graft versus host disease and persist in mice. J Exp Med 208 (2011), 2489–2496.
12. [12] Boros, P., Ochando, J., Zeher, M., Myeloid derived suppressor cells and autoimmunity. Hum Immunol 77 (2016), 631–636.
13. [13] Toda, A., Piccirillo, C.A., Development and function of naturally occurring CD4 + CD25 + regulatory T cells. J Leukoc Biol 80 (2006), 458–470.
14. [14] Dwivedi, M., Kemp, E.H., Laddha, N.C., Mansuri, M.S., Weetman, A.P., Begum, R., Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics. Autoimmun Rev 14 (2015), 49–56.
15. [15] Roncarolo, M.G., Bacchetta, R., Bordignon, C., Narula, S., Levings, M.K., Type 1 T regulatory cells. Immunol Rev 182 (2001), 68–79.
16. [16] Weiner, H.L., Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182 (2001), 207–214.
17. [17] Dwivedi, M., Kumar, P., Laddha, N.C., Kemp, E.H., Induction of regulatory T cells: a role for probiotics and prebiotics to suppress autoimmunity. Autoimmun Rev 15 (2016), 379–392.
18. [18] Papp, G., Szabó, K., Szekanecz, Z., Zeher, M., Follicular helper T cells in autoimmune diseases. Rheumatology (Oxford) 53 (2014), 1159–1160.
19. [19] Dhaeze, T., Stinissen, P., Liston, A., Hellings, N., Humoral autoimmunity: a failure of regulatory T cells?. Autoimmun Rev 14 (2015), 735–741.
20. [20] Yang, M., Rui, K., Wang, S., Lu, L., Regulatory B cells in autoimmune diseases. Cell Mol Immunol 10 (2013), 122–132.
21. [21] Ding, T., Yan, F., Cao, S., Ren, X., Regulatory B cell: new member of immunosuppressive cell club. Hum Immunol 76 (2015), 615–621.
22. [22] Baráth, S., Sipka, S., Aleksza, M., Szegedi, A., Szodoray, P., Végh, J., et al. Regulatory T-cells in peripheral blood of patients with mixed connective tissue disease. Scand J Rheumatol 35 (2006), 300–304.
23. [23] Dejaco, C., Duftner, C., Grubeck-Loebenstein, B., Schirmer, M., Imbalance of regulatory T cells in human autoimmune diseases. Immunology 117 (2006), 289–300.
24. [24] Liu, M.F., Wang, C.R., Fung, L.L., Wu, C.R., Decreased CD4 + CD25 + T-cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 59 (2004), 198–202.
25. [25] Szodoray, P., Papp, G., Horvath, I.F., Barath, S., Sipka, S., Nakken, B., et al. Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome. Clin Exp Immunol 157 (2009), 343–349.
26. [26] Valencia, X., Yarboro, C., Illei, G., Lipsky, P.E., Deficient CD4 + CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 178 (2007), 2579–2588.
27. [27] Grant, C.R., Liberal, R., Mieli-Vergani, G., Vergani, D., Longhi, M.S., Regulatory T-cells in autoimmune diseases: challenges, controversies and-yet-unanswered questions. Autoimmun Rev 14 (2015), 105–116.
28. [28] Szodoray, P., Nakken, B., Barath, S., Gaal, J., Aleksza, M., Zeher, M., et al. Progressive divergent shifts in natural and induced T-regulatory cells signify the transition from undifferentiated to definitive connective tissue disease. Int Immunol 20 (2008), 971–979.
29. [29] Lee, J.H., Wang, L.C., Lin, Y.T., Yang, Y.H., Lin, D.T., Chiang, B.L., Inverse correlation between CD4 regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 117 (2006), 280–286.
30. [30] Roncarolo, M.G., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., Levings, M.K., Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212 (2006), 28–50.
31. [31] Constant, S.L., Bottomly, K., Induction of Th1 and Th2 CD4 + T-cell responses: the alternative approaches. Annu Rev Immunol 15 (1997), 297–322.
32. [32] Moore, K.W., de Waal, Malefyt R., Coffman, R.L., O'Garra, A., Interleukin 10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001), 683–765.
33. [33] Kim, B.S., Park, Y.J., Chung, Y., Targeting IL-17 in autoimmunity and inflammation. Arch Pharm Res 39 (2016), 1537–1547.
34. [34] Steinman, L., A rush to judgment on Th17. J Exp Med 205 (2008), 1517–1522.
35. [35] Shin, M.S., Lee, N., Kang, I., Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol 23 (2011), 444–448.
36. [36] Lin, X., Rui, K., Deng, J., Tian, J., Wang, X., Wang, S., et al. Th17 cells play a critical role in the development of experimental Sjogren's syndrome. Ann Rheum Dis 74 (2015), 1302–1310.
37. [37] Papp, G., Horvath, I.F., Barath, S., Gyimesi, E., Sipka, S., Szodoray, P., et al. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 40 (2011), 205–210.
38. [38] Valencia, X., Lipsky, P.E., CD4 + CD25 + FoxP3 + regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol 3 (2007), 619–626.
39. [39] Zeher, M., Sjögren's syndrome. Zeher, M., Szodoray, P., (eds.) Sjögren's syndrome and associated disorders, 2006 Research signpost, 2006, Transworld Research Network, Kerala, 1–7.
40. [40] Szodoray, P., Nakken, B., Selected molecular aspects behind the clinical picture of Sjögren's syndrome. Zeher, M, Szodoray, P, (eds.) Sjögren's syndrome and associated disorders, 2006. Research signpost. Kerala: Transworld Research Network, 2006, 27–49.
41. [41] Ciccia, F., Guggino, G., Giardina, A., Ferrante, A., Carrubbi, F., Giacomelli, R., et al. The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome. Expert Rev Clin Immunol 10 (2014), 533–541.
42. [42] Szodoray, P., Alex, P., Jonsson, M.V., Knowlton, N., Dozmorov, I., Nakken, B., et al. Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 117 (2005), 168–176.
43. [43] Illes, A., Varoczy, L., Papp, G., Wilson, P.C., Alex, P., Jonsson, R., et al. Aspects of B-cell non-Hodgkin's lymphoma development: a transition from immune-reactivity to malignancy. Scand J Immunol 69 (2009), 387–400.
44. [44] Szodoray, P., Alex, P., Brun, J.G., Centola, M., Jonsson, R., Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 59 (2004), 592–599.
45. [45] Szabo, K., Papp, G., Dezso, B., Zeher, M., The histopathology of labial salivary glands in primary Sjögren's syndrome: focusing on follicular helper T cells in the inflammatory infiltrates. Mediators Inflamm, 2014, 2014, 631787.
46. [46] Szabo, K., Papp, G., Barath, S., Gyimesi, E., Szanto, A., Zeher, M., Follicular helper T cells may play an important role in the severity of primary Sjögren's syndrome. Clin Immunol 147 (2013), 95–104.
47. [47] Papp, G., Gyimesi, E., Szabó, K., Zöld, É., Zeher, M., Increased IL-21 expression induces granzyme B in peripheral CD5(+) B cells as a potential counter-regulatory effect in primary Sjögren's syndrome. Mediators Inflamm, 2016, 2016, 4328372.
48. [48] Tsokos, G.C., Systemic lupus erythematosus. N Engl J Med 365 (2011), 2110–2121.
49. [49] Aringer, M., Smolen, J.S., Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 13 (2004), 344–347.
50. [50] Rönnblom, L., Elkon, K.B., Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 6 (2010), 339–347.
51. [51] Niewold, T.B., Kelly, J.A., Flesch, M.H., Espinoza, L.R., Harley, J.B., Crow, M.K., Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 58 (2008), 2481–2487.
52. [52] Kariuki, S.N., Kirou, K.A., MacDermott, E.J., Barillas-Arias, L., Crow, M.K., Niewold, T.B., Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 182 (2009), 34–38.
53. [53] Vereecke, L., Beyaert, R., van Loo, G., The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 30 (2009), 383–391.
54. [54] Munroe, M.E., Vista, E.S., Guthridge, J.M., Thompson, L.F., Merrill, J.T., James, J.A., Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol 66 (2014), 1888–1899.
55. [55] Barath, S., Aleksza, M., Tarr, T., Sipka, S., Szegedi, G., Kiss, E., Measurement of natural (CD4 + CD25high) and inducible (CD4 + IL-10 +) regulatory T cells in patients with systemic lupus erythematosus. Lupus 16 (2007), 489–496.
56. [56] Bonelli, M., Savitskaya, A., von Dalwigk, K., Steiner, C.W., Aletaha, D., Smolen, J.S., et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 20 (2008), 861–868.
57. [57] Wong, C.K., Lit, L.C., Tam, L.S., Li, E.K., Wong, P.T., Lam, C.W., Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 127 (2008), 385–393.
58. [58] Doreau, A., Belot, A., Bastid, J., Riche, B., Trescol-Biemont, M.C., Ranchin, B., et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 10 (2009), 778–785.
59. [59] Alunno, A., Bartoloni, E., Bistoni, O., Nocentini, G., Ronchetti, S., Caterbi, S., et al. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol, 2012, 2012, 823085.
60. [60] Szabó, K., Papp, G., Szántó, A., Tarr, T., Zeher, M., A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren's syndrome and systemic lupus erythematosus. Clin Exp Immunol 183 (2016), 76–89.
61. [61] LeRoy, E.C., Medsger, T.A. Jr., Criteria for the classification of early systemic sclerosis. J Rheumatol 28 (2001), 1573–1576.
62. [62] Sakkas, L.I., Platsoucas, C.D., Is systemic sclerosis an antigen-driven T cell disease?. Arthritis Rheum 50 (2004), 1721–1733.
63. [63] Murata, M., Fujimoto, M., Matsushita, T., Hamaguchi, Y., Hasegawa, M., Takehara, K., et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?. J Dermatol Sci 50 (2008), 240–242.
64. [64] Deleuran, B., Abraham, D.J., Possible implication of the effector CD4 + T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 3 (2007), 682–683.
65. [65] Papp, G., Barath, S., Szegedi, A., Szodoray, P., Zeher, M., The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis. Clin Rheumatol 31 (2012), 1293–1299.
66. [66] Papp, G., Horvath, I.F., Gyimesi, E., Barath, S., Vegh, J., Szodoray, P., et al. The assessment of immune-regulatory effects of extracorporeal photopheresis in systemic sclerosis: a long-term follow-up study. Immunol Res 64 (2016), 404–411.
67. [67] Hoffman, R.W., Greidinger, E.L., Mixed connective tissue disease. Curr Opin Rheumatol 12 (2000), 386–390.
68. [68] Bodolay, E., Aleksza, M., Antal-Szalmás, P., Végh, J., Szodoray, P., Soltész, P., et al. Serum cytokine levels and type 1 and type 2 intracellular T cell cytokine profiles in mixed connective tissue disease. J Rheumatol 29 (2002), 2136–2142.
69. [69] Hajas, A., Szodoray, P., Barath, S., Sipka, S., Rezes, S., Zeher, M., et al. Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels. J Rheumatol 36 (2009), 1930–1936.
70. [70] Hajas, A., Sandor, J., Csathy, L., Csipo, I., Barath, S., Paragh, G., et al. Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 10 (2011), 317–324.
71. [71] Sagoo, P., Perucha, E., Sawitzki, B., Tomiuk, S., Stephens, D.A., Miqueu, P., et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120 (2010), 1848–1861.
72. [72] Larsen, C.P., Morris, P.J., Austyn, J.M., Migration of dendritic leukocytes form cardiac allografts into host spleens: a novel pathway for initiation of rejection. J Exp Med 171 (1990), 307–314.
73. [73] Alexander, S.I., Smith, N., Hu, M., Verran, D., Shun, A., Dorney, S., et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 358 (2008), 369–374.
74. [74] Takatsuki, M., Uemoto, S., Inomata, Y., Egawa, H., Kiuchi, T., Fujita, S., et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 72 (2001), 449–454.
75. [75] Fleming, B.D., Mosser, D.M., Regulatory macrophages: setting the threshold for therapy. Eur J Immunol 41 (2011), 2498–2502.
76. [76] Riquelme, P., Tomiuk, S., Kammler, A., Fändrich, F., Schlitt, H.J., Geissler, E.K., et al. IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther 21 (2013), 409–422.
77. [77] Hutchinson, J.A., Riquelme, P., Sawitzki, B., Tomiuk, S., Miqueu, P., Zuhayra, M., et al. Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol 187 (2011), 2072–2078.
78. −) prolong cardiac allograft survival in nonimmunosupressed recipients. Transplantation 62 (1996), 659–665.
79. [79] Lutz, M.B., Suri, R.M., Niimi, M., Ogilvie, A.L., Kukutsch, N.A., Rössner, S., et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 30 (2000), 1813–1822.
80. [80] Roelen, D.L., Schuurhuis, D.H., van den Boogaardt, D.E., Koekkoek, K., van Miert, P.P., van Schip, J.J., et al. Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells. Transplantation 76 (2003), 1608–1615.
81. [81] Ochando, J.C., Homma, C., Yang, Y., Hidalgo, A., Garin, A., Tacke, F., et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 7 (2006), 652–662.
82. [82] Tokita, D., Mazariegos, G.V., Zahorchak, A.F., Chien, N., Abe, M., Raimondi, G., et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 85 (2008), 369–377.
83. [83] Matta, B.M., Castellaneta, A., Thomson, A.W., Tolerogenic plasmacytoid DC. Eur J Immunol 40 (2010), 2667–2676.
84. [84] Zhang, B., Liu, R., Shi, D., Liu, X., Chen, Y., Dou, X., et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 113 (2009), 46–57.
85. [85] Ge, W., Jiang, J., Baroja, M.L., Arp, J., Zassoko, R., Liu, W., et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 9 (2009), 1760–1772.
86. [86] Dutta, P., Hullett, D.A., Roenneburg, D.A., Torrealba, J.R., Sollinger, H.W., Harn, D.A., et al. Lacto-N-fucopentaose III, a pentasaccharide, prolongs heart transplant survival. Transplantation 90 (2010), 1071–1078.
87. [87] Srivastava, M.K., Zhu, L., Harris-White, M., Kar, U.K., Huang, M., Johnson, M.F., et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One, 7, 2012, e40677.
88. [88] Luan, Y., Mosheir, E., Menon, M.C., Wilson, D., Woytovich, C., Ochando, J., et al. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4(+) Foxp3(+) Treg expansion. Am J Transplant 13 (2013), 3123–3131.
89. [89] Le Blanc, K., Mougiakakos, D., Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 12 (2012), 383–396.
90. [90] Nauta, A.J., Kruisselbrink, A.B., Lurvink, E., Willemze, R., Fibbe, W.E., Mesenchymal stem cells inhibit generation and function of both CD34 +−derived and monocyte-derived dendritic cells. J Immunol 177 (2006), 2080–2087.
91. [91] Spaggiari, G.M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M.C., Moretta, L., Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111 (2008), 1327–1333.
92. [92] Prigione, I., Benvenuto, F., Bocca, P., Battistini, L., Uccelli, A., Pistoia, V., Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 27 (2009), 693–702.
93. [93] Casiraghi, F., Azzollini, N., Cassis, P., Imberti, B., Morigi, M., Cugini, D., et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 181 (2008), 3933–3946.
94. [94] Ding, Y., Xu, D., Feng, G., Bushell, A., Muschel, R.J., Wood, K.J., Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes 58 (2009), 1797–1806.
95. [95] Carvalho-Gaspar, M., Jones, N.D., Luo, S., Martin, L., Brook, M.O., Wood, K.J., Location and time-dependent control of rejection by regulatory T cells culminates in a failure to generate memory T cells. J Immunol 180 (2008), 6640–6648.
96. [96] Graca, L., Cobbold, S.P., Waldmann, H., Identification of regulatory T cells in tolerated allografts. J Exp Med 195 (2002), 1641–1646.
97. + regulatory T cells is vital for infectious transplantation tolerance. J Exp Med 208 (2011), 2043–2053.
98. [98] Ciubotariu, R., Li, J., Colovai, A.I., Platt, J.L., Cortesini, R., Suciu Foca Cortesini, N., Human xenospecific T suppressor cells inhibit T helper cell proliferation to porcine aortic endothelial cells, and NF-kappaB activity in porcine APC. Hum Immunol 62 (2001), 470–478.
99. + tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 16 (2004), 1055–1068.
100. − regulatory T cells. J Immunol 161 (1998), 5193–5202.
101. [101] Choi, J., Enis, D.R., Koh, K.P., Shiao, S.L., Pober, J.S., T lymphocyte-endothelial cell interactions. Annu Rev Immunol 22 (2004), 683–709.
102. − T suppressor cells on the acute rejection responses in rat liver transplantation. Transplant Proc 39 (2007), 3396–3403.
103. − T-suppressor cells. Hum Immunol 66 (2005), 252–257.
104. − T-suppressor cells in adult-to-adult living donor liver transplant recipients. Transplant Proc 41 (2009), 4229–4231.
105. + T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 8 (2008), 338–347.
106. + T cells as regulatory versus memory T cells. J Immunol 185 (2010), 803–807.
107. + regulatory T cells. Am J Transplant 14 (2014), 39–48.
108. [108] Li, Y., Koshiba, T., Yoshizawa, A., Yonekawa, Y., Masuda, K., Ito, A., et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 4 (2004), 2118–2125.
109. [109] Mauri, C., Gray, D., Mushtaq, N., Londei, M., Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197 (2003), 489–501.
110. [110] Puig-Pey, I., Bohne, F., Benítez, C., López, M., Martínez-Llordella, M., Oppenheimer, F., et al. Characterization of γδ T cell subsets in organ transplantation. Transpl Int 23 (2010), 1045–1055.
111. [111] Haas, M., Sis, B., Racusen, L.C., Solez, K., Glotz, D., Colvin, R.B., et al. Banff meeting report writing committee. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibodyassociated arterial lesions. Am J Transplant 14 (2014), 272–283.
112. [112] Walters, G.D., Vinuesa, C.G., T follicular helper cells in transplantation. Transplantation 100 (2016), 1650–1655.
113. [113] de Graav, G.N., Dieterich, M., Hesselink, D.A., Boer, K., Clahsen-van Groningen, M.C., Kraaijeveld, R., et al. Follicular T helper cells and humoral reactivity in kidney transplant patients: Tfh cells in kidney transplantation. Clin Exp Immunol 180 (2015), 329–340.
114. [114] Parker, D.C., Greiner, D.L., Phillips, N.E., Appel, M.C., Steele, A.W., Durie, F.H., et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A 92 (1995), 9560–9564.
115. [115] Niimi, M., Pearson, T.C., Larsen, C.P., Alexander, D.Z., Hollenbaugh, D., Aruffo, A., et al. The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo. J Immunol 161 (1998), 5331–5337.
116. [116] Deng, S., Moore, D.J., Huang, X., Lian, M.M., Mohiuddin, M., Velededeoglu, E., et al. Cutting edge: transplant tolerance induced by anti-CD45RB requires B lymphocytes. J Immunol 178 (2007), 6028–6032.
117. [117] Huang, X., Moore, D.J., Mohiuddin, M., Lian, M.M., Kim, J.I., Sonawane, S., et al. Inhibition of ICAM-1/LFA-1 interactions prevents B-cell-dependent anti-CD45RB-induced transplantation tolerance. Transplantation 85 (2008), 675–680.
118. [118] Zhao, G., Moore, D.J., Lee, K.M., Kim, J.I., Duff, P.E., O'Connor, M.R., et al. An unexpected counter-regulatory role of IL-10 in B-lymphocyte-mediated transplantation tolerance. Am J Transplant 10 (2010), 796–801.
119. [119] Murray, P.J., Wynn, T.A., Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11 (2011), 723–737.
120. [120] Lee, K.M., Kim, J.I., Stott, R., Soohoo, J., O'Connor, M.R., Yeh, H., et al. Anti-CD45RB/anti-TIM-1-induced tolerance requires regulatory B cells. Am J Transplant 12 (2012), 2072–2078.
121. [121] Le Texier, L., Thebault, P., Lavault, A., Usal, C., Merieau, E., Quillard, T., et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant 11 (2011), 429–438.
122. [122] Pallier, A., Hillion, S., Danger, R., Giral, M., Racapé, M., Degauque, N., et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 78 (2010), 503–513.
123. [123] Newell, K.A., Asare, A., Kirk, A.D., Gisler, T.D., Bourcier, K., Suthanthiran, M., et al. Immune Tolerance Network ST507 Study Group. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 120 (2010), 1836–1847.
124. [124] Brouard, S., Mansfield, E., Braud, C., Li, L., Giral, M., Hsieh, S.C., et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 104 (2007), 15448–15453.
125. [125] Clatworthy, M.R., Watson, C.J., Plotnek, G., Bardsley, V., Chaudhry, A.N., Bradley, J.A., et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 360 (2009), 2683–2685.
126. [126] Wu, J., Yi, S., Ouyang, L., Jimenez, E., Simond, D., Wang, W., et al. In vitro expanded human CD4 + CD25 + regulatory T cells are potent suppressors of T-cell-mediated xenogeneic responses. Transplantation 85 (2008), 1841–1848.
127. [127] Liao, J., Chang, C., Wu, H., Lu, Q., Cell-based therapies for systemic lupus erythematosus. Autoimmun Rev 14 (2015), 43–48.
128. [128] Petrillo, M.G., Ronchetti, S., Ricci, E., Alunno, A., Gerli, R., Nocentini, G., et al. GITR + regulatory T cells in the treatment of autoimmune diseases. Autoimmun Rev 14 (2015), 117–126.
129. + regulatory T cell therapy in transplantation. J Mol Cell Biol 4 (2012), 11–21.
130. regs) with minimal loss of in vivo functional activity. Sci Transl Med, 3, 2011, 83ra41.
131. [131] Roncarolo, M.G., Battaglia, M., Regulatory T-cell immunotherapy for tolerance to selfantigens and alloantigens in humans. Nat Rev Immunol 7 (2007), 585–588.
132. [132] Hester, J., Schiopu, A., Nadig, S.N., Wood, K.J., Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am J Transplant 12 (2012), 2008–2016.
133. [133] Maggi, J., Schafer, C., Ubilla-Olguín, G., Catalán, D., Schinnerling, K., Aguillón, J.C., Therapeutic potential of hyporesponsive CD4(+) T cells in autoimmunity. Front Immunol, 6, 2015, 488.
134. [134] Volchenkov, R., Karlsen, M., Jonsson, R., Appel, S., Type 1 regulatory T cells and regulatory B cells induced by tolerogenic dendritic cells. Scand J Immunol 77 (2013), 246–254.
135. [135] Menon, M., Blair, P.A., Isenberg, D.A., Mauri, C., A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity 44 (2016), 683–697.
136. [136] Di Caro, V., Phillips, B., Engman, C., Harnaha, J., Trucco, M., Giannoukakis, N., Retinoic acid-producing, ex-vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B lymphocytes. Clin Exp Immunol 174 (2013), 302–317.
137. [137] Llanos, C., Mackern-Oberti, J.P., Vega, F., Jacobelli, S.H., Kalergis, A.M., Tolerogenic dendritic cells as a therapy for treating lupus. Clin Immunol 148 (2013), 237–245.
138. [138] Giannoukakis, N., Phillips, B., Finegold, D., Harnaha, J., Trucco, M., Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 34 (2011), 2026–2032.
139. [139] Benham, H., Nel, H.J., Law, S.C., Mehdi, A.M., Street, S., Ramnoruth, N., et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med, 290, 2015, 290ra87.
140. [140] Lisianyi, M.I., Mesenchymal stem cells and their immunological properties. Fiziol Zh 59 (2013), 126–134.
141. [141] Wang, D., Li, J., Zhang, Y., Zhang, M., Chen, J., Li, X., et al. Umbilical cordmesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther, 16, 2014, R79.
142. [142] Peng, Y., Ke, M., Xu, L., Liu, L., Chen, X., Xia, W., et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 95 (2013), 161–168.
143. [143] Tan, J., Wu, W., Xu, X., Liao, L., Zheng, F., Messinger, S., et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307 (2012), 1169–1177.
144. [144] Dilek, N., Poirier, N., Usal, C., Martinet, B., Blancho, G., Vanhove, B., Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5. J Immunol 188 (2012), 4209–4216.
145. [145] Chou, H.S., Hsieh, C.C., Charles, R., Wang, L., Wagner, T., Fung, J.J., et al. Myeloid-derived suppressor cells protect islet transplants by B7-H1 mediated enhancement of T regulatory cells. Transplantation 93 (2012), 272–282.
146. [146] Dilek, N., Vuillefroy de Silly, R., Blancho, G., Vanhove, B., Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. Front Immunol, 3, 2012, 208.
147. [147] Hutchinson, J.A., Riquelme, P., Brem-Exner, B.G., Schulze, M., Matthäi, M., Renders, L., et al. Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 21 (2008), 728–741.
148. [148] Hutchinson, J.A., Brem-Exner, B.G., Riquelme, P., Roelen, D., Schulze, M., Ivens, K., et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 21 (2008), 742–754.
149. [149] Hutchinson, J.A., Roelen, D., Riquelme, P., Brem-Exner, B.G., Witzke, O., Philipp, T., et al. Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells. Transpl Int 21 (2008), 808–813.
150. [150] Geissler, E.K., The ONE Study compares cell therapy products in organ transplantation: introduction to a review series on suppressive monocyte-derived cells. Transpl Res, 1, 2012, 11.